Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly & Co filed a Form 25 via the New York Stock Exchange to remove its 1.625% Notes Due 2026 from listing and registration. The Exchange certified compliance with 17 CFR 240.12d2-2 and the issuer confirmed voluntary withdrawal procedures. The notice is signed by Tyler Mastronardi of Market Watch.
Lilly Endowment Inc. reported proposed and recent dispositions of Common Stock of Eli Lilly and Company under a Form 144 notice. The filing lists a proposed block of 38,400,000 shares to be sold and multiple completed sales in May 2026, including tranches on May 13, May 21, and May 22 totaling hundreds of thousands of shares each. The filing lists transaction dates and gross proceeds for each reported sale.
Lilly Endowment Inc. reported multiple sales of Eli Lilly and Company common stock in May 2026. The filing lists specific transactions including 05/13/2026 sale of 256,365 shares for $259,024,427.96 and 05/21/2026 sale of 290,980 shares for $301,996,706.49.
Eli Lilly and Company completed an offering of multiple series of senior notes, generating approximately $8.94 billion in net proceeds after underwriting discounts. The deal includes floating rate notes due 2028 and 2029, and fixed rate notes maturing between 2029 and 2066.
The floating notes pay quarterly interest at Compounded SOFR plus 0.350% for the 2028 series and 0.460% for the 2029 series. The fixed notes pay semi-annual coupons ranging from 4.375% to 5.700%. All notes were issued under Eli Lilly’s existing Indenture and sold via a syndicate led by major global underwriters.
If the Centessa Acquisition is not completed by the agreed Outside Date or is abandoned, Eli Lilly must redeem the 2029 floating notes and several fixed tranches at 101% of principal plus accrued interest under a Centessa Special Mandatory Redemption, while the 2028 floating notes and the long-dated 2056 and 2066 notes are excluded.
Issuer affiliate notified proposed sales of common stock under Form 144. The filing lists multiple open-market dispositions by Lilly Endowment Inc. with specific trades reported on 05/06/2026, 05/11/2026, 05/12/2026, and 05/13/2026. The excerpt also shows a J.K. Lilly Sr. Trust holding figure of 38,400,000 shares in the securities section.
ELI LILLY & Co director Gabrielle Sulzberger received a stock award equivalent to 5.018 shares of common stock, valued at $988.09 per share. The award was not a market purchase but a grant reported as an acquisition.
According to the disclosure, Sulzberger elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, instead of taking cash. These stock units will be settled in shares of common stock after her separation from service. Following this grant, her directly held and reported common stock interest totals 2,986.617 shares.
LUCIANO JUAN R reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director Juan R. Luciano received an equity award of 16.109 shares of common stock on May 18, 2026, valued at $988.09 per share. According to the filing, he elected to defer this grant into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this award, he directly holds 16,850.832 shares of Lilly common stock.
ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award, not an open-market trade. He acquired 10.036 shares of common stock on May 18, 2026 at a reference price of $988.09 per share through a grant.
Under the Lilly Directors' Deferral Plan, he elected to defer this award as stock units, to be settled in common shares after his separation from service. Following this grant, his direct holdings increased to 75,279.592 shares of Lilly common stock.
ELI LILLY & Co director Ralph Alvarez reported an acquisition of 12.566 shares of common stock at $988.0900 per share as a grant or award. At his election, this amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following the transaction, he directly holds 55,627.279 shares of common stock and indirectly holds 758 shares by trust, while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Eli Lilly and Company is offering $9,000,000,000 of unsecured notes in multiple series due 2028 through 2066, including floating-rate notes tied to Compounded SOFR and several fixed-rate notes with coupons from 4.150% to 5.700%. The offering proceeds are expected to be used for general corporate purposes, including repayment of commercial paper and potentially to fund upfront cash consideration and fees for the pending acquisitions of Centessa Pharmaceuticals plc and Kelonia Therapeutics, Inc. The Centessa-related series (the Centessa Mandatorily Redeemable Notes) include a special mandatory redemption provision that requires redemption at 101% of principal plus accrued interest if the Centessa Acquisition is not consummated by specified outside dates or if Lilly elects not to pursue the acquisition.